Moreover, the immunofluorescence analyses of these distinct molecular biomarkers with the CD133 stem cell-like marker have also indicated that these oncogenic products were overexpressed in a small subset of CD133+ PC cells and the bulk mass of CD133− PC cells in prostatic adenocarcinoma specimens relative to normal prostatic tissues (Figure 4 and Figure S1). This evidence concerns the gene PROM1 and prostate adenocarcinoma.